Context: - Delta checks serve as a patient-based quality control tool to detect testing problems.
Objective: - To evaluate delta check practices and outcomes.
Design: - Q-Probes participants provided information about delta check policies and procedures. Information about investigations, problems, and corrective actions was prospectively collected for up to 100 testing episodes involving delta check alerts.
Results: - Among 4505 testing episodes involving 6541 delta check alerts, the median frequencies of actions taken among 49 laboratories were clinical review, 38.0%; retest, 25.0%, or recheck, 20.2%; current specimen, nothing, 15.4%; analytical check, 5.0%; other; 2%; and retest or check previous specimen, 0%. Rates of any action taken by analyte ranged from 84 of 179 (46.9%) for glucose to 748 of 868 (86.2%) for hemoglobin and potassium. Among 4505 testing episodes, nontesting problems included physiologic causes (1472; 32.7%); treatment causes (1318; 19.2%); and transfusion causes (846; 9.9%). Testing problems included 77 interference (1.7%), 62 contamination (1.4%), 51 clotting (1.1%), 27 other (0.6%), 12 mislabeling (0.3%), and 5 analytical (0.1%). Testing problems by analyte ranged from 13 of 457 (2.8%) for blood urea nitrogen to 12 of 46 (26.1%) for mean corpuscular hemoglobin concentration. Using more delta check analytes was associated with detecting more testing problems (P = .04). More delta check alerts per testing episode resulted in more actions taken (P = .001) and more problems identified (P < .001). The most common outcome among 4500 testing episodes was reporting results without modifications or comments in 2512 (55.8%); results were not reported in 136 (3.0%).
Conclusions: - Actions taken in response to delta check alerts varied widely, and most testing problems detected were preanalytical. Using a higher number of different analytes and evaluating previous specimens may improve delta check practices.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5858/arpa.2016-0161-CP | DOI Listing |
Clin Chem
January 2025
Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Background: Multianalyte machine learning (ML) models can potentially identify previously undetectable wrong blood in tube (WBIT) errors, improving upon current single-analyte delta check methodology. However, WBIT detection model performance has not been assessed in a real-world, low-prevalence context. To estimate real-world positive predictive values, we propose a methodology to assess WBIT detection models by evaluating the impact of missing data and by using a "low prevalence" validation data set.
View Article and Find Full Text PDFJ Orthop Surg Res
January 2025
Center of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Background: Delta large-channel endoscopy and unilateral biportal endoscopy (UBE) are prominent minimally invasive techniques for treating lumbar spinal stenosis, known for minimal tissue damage, clear visualization, and quick recovery. However, rigorous controlled research comparing these procedures is scarce, necessitating further investigation into their respective complications and long-term effectiveness. This randomized controlled trial aims to compare their perioperative outcomes, focusing on postoperative recovery and complications over time.
View Article and Find Full Text PDFJ Appl Lab Med
January 2025
Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, IL, United States.
Background: Our institution involves our pathology residents in departmental quality initiatives and in identifying needs for operational improvements. The solutions achieved by these projects have effects beyond the laboratory, and ultimately help to improve diagnostic stewardship by supporting the clinician's ability to obtain necessary biochemical information at the right time. A project highlighting a successful venture is described here in which our investment in new total laboratory automation was not meeting our goals for autoverification rates, resulting in less than expected improvements to turnaround times (TAT).
View Article and Find Full Text PDFMikrobiyol Bul
October 2024
University of Health Sciences, Ankara Bilkent City Health Application and Research Center, Clinic of Medical Microbiology, Ankara, Türkiye.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has mutated at a high rate since the beginning of the pandemic, leading to the formation of different variants. Alpha, Beta, Gamma, Delta and Omicron have emerged as concerning variants identified by the World Health Organization (WHO). The Omicron variant and its sublineages became dominant worldwide in 2022.
View Article and Find Full Text PDFMagn Reson Chem
January 2025
Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Graz, Graz, Austria.
Besides classic illegal drugs, numerous designer drugs, also called new psychoactive substances (NPSs), are available on the global drug market. One of the biggest and fastest-growing substance classes comprises the synthetic cannabinoids. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 254 out of 950 monitored substances belong to this group of NPS, with 9 new cannabinoids registered for the first time in 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!